BamSEC and AlphaSense Join Forces
Learn More

Arrowhead Pharmaceuticals Inc.

NASDAQ: ARWR    
Share price (12/20/24): $19.45    
Market cap (12/20/24): $2.420 billion
Search in Documents
Key Exhibits
External Links

Underwriting Agreements Filter

EX-1
from SC 13G 1 page Exhibit 1 Joint Filing Agreement Pursuant to Rule 13d-1
12/34/56
EX-1.1
from 8-K 44 pages Underwriting agreement
12/34/56
EX-1.1
from 8-K 35 pages Open Market Sale Agreement1
12/34/56
EX-1.2
from S-3ASR 39 pages Open Market Sale Agreementsm
12/34/56
EX-1.1
from 10-Q 39 pages Open Market Sale Agreementsm
12/34/56
EX-1
from SC 13G/A 2 pages Joint Filing Statement Pursuant to Rule 13d-1
12/34/56
EX-1.1
from 8-K 42 pages 4,000,000 Shares Arrowhead Pharmaceuticals, Inc. Underwriting Agreement
12/34/56
EX-1
from SC 13G/A 2 pages Joint Filing Statement Pursuant to Rule 13d-1
12/34/56
EX-1
from SC 13G 2 pages Joint Filing Statement Pursuant to Rule 13d-1
12/34/56
EX-1.1
from 8-K 39 pages 10,000,000 Shares Arrowhead Pharmaceuticals, Inc. Underwriting Agreement
12/34/56
EX-1
from SC 13D/A ~5 pages Joint Filing Agreement
12/34/56
EX-1
from SC 13D ~1 page Joint Filing Agreement
12/34/56
EX-1.1
from 8-K 40 pages 5,500,000 Shares Arrowhead Research Corporation Underwriting Agreement
12/34/56
EX-1
from SC 13G/A 1 page Exhibit 1 Joint Filing Agreement
12/34/56
EX-1.2
from 8-K 2 pages Strictly Confidential Christopher Anzalone, PH.D. Chief Executive Officer Arrowhead Research Corporation 225 South Lake Avenue, Suite 1050 Pasadena, California 91101 Dear Mr. Anzalone
12/34/56
EX-1.1
from 8-K 10 pages Strictly Confidential Arrowhead Research Corporation 225 South Lake Avenue, Suite 1050 Pasadena, Ca 91101 Attn: Christopher Anzalone PH.D. Dear Dr. Anzalone
12/34/56
EX-1.1
from 8-K 10 pages Strictly Confidential Arrowhead Research Corporation 225 South Lake Avenue, Suite 1050 Pasadena, Ca 91101 Attn: Christopher Anzalone PH.D. Dear Dr. Anzalone
12/34/56
EX-1.1
from 8-K 12 pages Strictly Confidential Arrowhead Research Corporation 201 South Lake Avenue 3rd Floor Pasadena, Ca 91101 Attn: Christopher Anzalone PH.D. Dear Mr. Anzalone
12/34/56
EX-1
from 8-K 1 page January 8, 2004 Securities and Exchange Commission Washington, D.C. 20549 Commissioners: We Have Read Interactive Group, Inc.'s Statements Included Under Item 4 of Its Form 8-K for January 8, 2004, and We Agree With Such Statements Concerning Our Firm. /S/ McGladrey & Pullen, Llp McGladrey & Pullen, Llp <page>
12/34/56
EX-1
from DEF 14C 1 page Underwriting agreement
12/34/56